Arnold J, Jacob J T, Riley B
J Pharm Sci. 1980 Dec;69(12):1416-8. doi: 10.1002/jps.2600691217.
The bioavailability of a new, slow-release potassium chloride product consisting of coated beads in a hard gelatin capsule was compared with the bioavailability of two marketed products, an elixir and a slow-release tablet, by determining the urinary excretion of potassium. Twelve healthy male volunteers were dosed with a total of 80 mEq of potassium, in a single dose for the capsule and tablet and in three 26.6-mEq doses at 6-hr intervals for the elixir. Mean recoveries in 24-hr urine potassium levels from all three dosage forms after subtracting normal urine potassium excretion levels were 50.8% from the capsule, 53.9% from the elixir, and 63.1% from the tablet. Maximum excretion rates were reached at 2.0 hr for the elixir, 6.8 hr for the capsule, and 4.0 hr for the tablet. Fewer side effects were reported with the capsule than with the elixir and tablet.
通过测定钾的尿排泄量，比较了一种新的缓释氯化钾产品（由硬明胶胶囊中的包衣微丸组成）与两种市售产品（一种酏剂和一种缓释片剂）的生物利用度。12名健康男性志愿者服用了总量为80 mEq的钾，胶囊和片剂为单次给药，酏剂则分三次给药，每次26.6 mEq，间隔6小时。从三种剂型中减去正常尿钾排泄量后，24小时尿钾水平的平均回收率分别为：胶囊50.8%，酏剂53.9%，片剂63.1%。酏剂在2.0小时达到最大排泄率，胶囊在6.8小时，片剂在4.0小时。与酏剂和片剂相比，服用胶囊报告的副作用更少。
